An agent approved for managing type 2 diabetes which reduces glucose resorption in the kidneys by inhibiting the sodium glucose co-transporter (SGLT2). Canagliflozin therapy is associated with weight loss and reduced blood pressure.
Adverse effects Fungal infections of female genital tract, urinary tract infections, increased urination.
Proprietary name Invokana
Reference Product literature, Janssen Pharmaceuticals